<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Uremic polyneuropathy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Uremic polyneuropathy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Uremic polyneuropathy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Biff F Palmer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Uremic polyneuropathy is common among patients with end-stage kidney disease (ESKD) [<a href="#rid1">1-3</a>]. Polyneuropathy generally develops only in patients with significantly reduced glomerular filtration rate (GFR) and is an indication to initiate dialysis. However, patients already being adequately dialyzed may also develop polyneuropathy, although, among such patients, the polyneuropathy is often subclinical and detectable only by electrophysiologic studies.</p><p>This topic reviews uremic polyneuropathy. Restless leg syndrome, and other neurologic manifestations associated with uremia or dialysis are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/16197.html" rel="external">"Sleep disorders in end-stage kidney disease", section on 'Restless legs syndrome and periodic limb movement disorder'</a>.)</p><p class="headingAnchor" id="H131431718"><span class="h1">PATHOLOGY AND PATHOGENESIS</span><span class="headingEndMark"> — </span>Uremic polyneuropathy is a distal, symmetrical, mixed sensorimotor neuropathy that is characterized by demyelination and axonal degeneration [<a href="#rid1">1</a>]. Axonal degeneration appears to be the primary abnormality and results in secondary segmental demyelination. These changes are most severe distally, and longer axons are affected first. In addition to peripheral nerve involvement, demyelination of the posterior columns and other portions of the central nervous system has also been described [<a href="#rid2">2</a>].</p><p>The cause of uremic polyneuropathy is not known [<a href="#rid2">2</a>]. Factors that have been suggested to contribute include deficiencies of thiamine, zinc, and <a class="drug drug_general" data-topicid="120386" href="/d/drug information/120386.html" rel="external">biotin</a> and decreased transketolase activity [<a href="#rid4">4</a>]. Increases in phenols, myoinositol, beta2-microglobulin and other middle-molecular-weight substances, hyperparathyroidism, and hyperkalemia have also been suggested to contribute [<a href="#rid5">5-8</a>].  </p><p class="headingAnchor" id="H131431988"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Uremic polyneuropathy is common among patients on dialysis and patients with nondialysis chronic kidney disease (CKD). Among patients on dialysis, 60 to 100 percent of patients have electrophysiologic signs of impaired nerve function, although a lower percentage of patients are symptomatic [<a href="#rid9">9-12</a>].</p><p>The best data regarding prevalence among patients with nondialysis CKD are from an observational study that included 100 patients not on dialysis between ages 18 to 65 years who had serum creatinine &gt;2 mg/dL [<a href="#rid13">13</a>]. Sixty-four percent of patients had symptomatic polyneuropathy, and an additional 6 percent were asymptomatic but had abnormalities observed on nerve conduction studies or elicited with careful clinical exam. The prevalence of neuropathy increased with severity of kidney dysfunction; among patients with creatinine 2 to 3.4, 3.5 to 4.9, and &gt;5 mg/dL, the prevalence of neuropathy was 35, 89, and 100 percent, respectively.</p><p>Uremic polyneuropathy is more common in males than females.</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients with uremic polyneuropathy initially present with sensory symptoms involving the distal aspect of the lower extremities. Early sensory symptoms include paresthesias such as tingling or prickling. Burning pain develops as neuropathy becomes more severe.</p><p>Symptoms progress proximally; once the sensory defects have moved to or above the knees, patients may develop symptoms in their hands.</p><p>Patients with more advanced disease develop motor symptoms including weakness of distal muscles, myoclonus, and even paralysis. These symptoms rarely if ever occur before the onset of sensory symptoms.</p><p>On physical examination, the initial findings in uremic polyneuropathy include loss of position and vibration sense in the toes and decreased deep tendon reflexes, beginning with the Achilles reflex. Paradoxical heat sensation is another sensory manifestation, in which application of low-temperature stimuli evokes the sensation of high temperature [<a href="#rid14">14</a>].</p><p>Among patients with more advanced disease, physical examination may reveal muscle atrophy.</p><p class="headingAnchor" id="H5"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of polyneuropathy is suggested by the clinical presentation and confirmed by electrophysiologic studies [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/5277.html" rel="external">"Evaluation of peripheral nerve and muscle disease", section on 'Diagnostic testing'</a>.)</p><p>Motor nerve conduction velocity, often measured in the peroneal nerve, is the most common parameter used to assess motor function. Sensory nerve conduction velocity of the sural nerve is even more sensitive in detecting early dysfunction but is not as widely used.</p><p>The nerves from the extremity that has the fistula or graft should not be used for electrophysiologic studies, since results are affected by local lesions related to the dialysis access [<a href="#rid11">11,16</a>].</p><p>In addition to early diagnosis, electrophysiologic testing can also be used to monitor the course of disease once kidney replacement therapy is initiated; however, this is rarely done if clinical symptoms of neuropathy respond to dialysis.</p><p class="headingAnchor" id="H131431995"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Uremic polyneuropathy is difficult to distinguish from multiple other types of polyneuropathies caused by diseases that also cause chronic kidney disease (CKD). These diseases include diabetes mellitus, systemic lupus erythematosus, systemic vasculitides, multiple myeloma, amyloidosis, and graft-versus-host disease. These diseases are generally excluded by history.</p><p>A rapidly evolving motor polyneuropathy has been described among patients with end-stage kidney disease (ESKD), with features of Guillain-Barré syndrome [<a href="#rid17">17-19</a>] (see  <a class="medical medical_review" href="/d/html/5137.html" rel="external">"Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis"</a>). In almost all cases, the underlying kidney disease was membranous nephropathy [<a href="#rid17">17-19</a>]. However, the acute presentation and predominance of motor symptoms distinguishes this entity from uremic polyneuropathy.</p><p>A complete differential diagnosis and the diagnostic evaluation of polyneuropathy are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/5284.html" rel="external">"Overview of polyneuropathy"</a> and  <a class="medical medical_review" href="/d/html/5284.html" rel="external">"Overview of polyneuropathy", section on 'Etiology and pathogenesis'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Among patients with chronic kidney disease (CKD) who are not yet on dialysis, uremic polyneuropathy is an indication for kidney replacement therapy, including either dialysis or transplantation. Both dialysis and transplantation are effective in stabilizing or improving the symptoms of polyneuropathy, although transplantation is generally more effective [<a href="#rid7">7,20</a>]. It is likely that hemodialysis and continuous ambulatory peritoneal dialysis (CAPD) are equally effective in reducing symptoms of polyneuropathy.</p><p>Among patients who are on dialysis, symptoms of uremic neuropathy are an indication to determine if the dialysis prescription is adequate and usually to increase the amount of delivered dialysis, even if the minimum target Kt/V is being achieved with the current prescription. (See  <a class="medical medical_review" href="/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis"</a>.)</p><p>Some patients will have persistent symptoms of neuropathy despite increasing the amount of dialysis. For suitable transplantation candidates, transplantation may reverse the symptoms of neuropathy, even when dialysis has failed to do so [<a href="#rid20">20</a>]. However, some patients are not suitable transplant candidates, and even suitable candidates may be waiting for a deceased-donor kidney for a number of years. In addition, some patients elect not to undergo dialysis despite the onset of uremia.</p><p>For such patients, pharmacologic treatment of neuropathy may be effective.</p><p>Based upon studies of nonuremic polyneuropathy, <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> may be used. A suggested dose is 100 to 200 mg per day plus an additional 300 mg after each hemodialysis session for those on dialysis [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/5284.html" rel="external">"Overview of polyneuropathy", section on 'Treatment of symptoms and prevention of complications'</a>.)</p><p>If <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> is ineffective or not tolerated, a tricyclic antidepressant may be used (eg, <a class="drug drug_general" data-topicid="9329" href="/d/drug information/9329.html" rel="external">desipramine</a> 10 to 50 mg at night).</p><p>Physical exercise may prevent the loss of muscle power [<a href="#rid10">10</a>]. As with other types of neuropathy, the appropriate use of ankle-foot orthoses, splints, and walking assistance devices can significantly improve lifestyle in the face of significant disability. (See  <a class="medical medical_review" href="/d/html/5284.html" rel="external">"Overview of polyneuropathy"</a>.)</p><p>Patients with distal polyneuropathy are at increased risk for developing foot ulcers; proper foot and nail care is especially important in this population. Regular visits to a podiatrist can also help prevent problems.</p><p class="headingAnchor" id="H434349410"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The degree to which polyneuropathy improves with dialysis is directly related to the severity of clinical symptoms prior to initiation. Complete resolution may occur among patients who have only mild sensory symptoms [<a href="#rid1">1</a>], although subclinical abnormalities may still be detectable by electrophysiologic testing [<a href="#rid22">22</a>].</p><p>Among patients with more severe neurologic symptoms, neurologic symptoms may persist even after many years of dialysis.</p><p>Kidney transplantation completely reverses the symptoms of neuropathy, except among the most severely affected patients. The clinical course after transplantation is often biphasic [<a href="#rid23">23</a>]. There is initial rapid improvement, which occurs over days or weeks; this phase is then followed by continued, gradual improvement over a period of several months.</p><p class="headingAnchor" id="H24108764"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Uremic polyneuropathy is common among patients on dialysis and patients with nondialysis chronic kidney disease (CKD). In patients with nondialysis CKD, the prevalence increases as kidney function declines. Uremic polyneuropathy is more common in males than females. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Uremic polyneuropathy is characterized by demyelination and axonal degeneration. The cause is not known but may involve deficiencies of thiamine, zinc, and <a class="drug drug_general" data-topicid="120386" href="/d/drug information/120386.html" rel="external">biotin</a> and decreased transketolase activity. Increases in phenols, myoinositol, beta2-microglobulin and other middle-molecular-weight substances, and hyperparathyroidism may also contribute. (See <a class="local">'Pathology and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Patients initially present with sensory symptoms involving the distal aspect of the lower extremities. Early sensory symptoms include paresthesias such as tingling or prickling, and, as neuropathy becomes more severe, burning pain develops. Patients with more advanced disease develop motor symptoms including weakness of distal muscles, myoclonus, and even paralysis. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Findings on physical examination</strong> – Physical findings include loss of position and vibration sense in the toes and decreased deep tendon reflexes, beginning with the Achilles reflex. Among patients with more advanced disease, the physical examination may reveal muscle atrophy. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis is suggested by a characteristic clinical presentation and confirmed by electrophysiologic studies. Uremic polyneuropathy is difficult to distinguish from other neuropathies caused by diseases that also cause CKD. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment by initiation or intensification of kidney replacement therapy</strong> – Symptoms of uremic polyneuropathy are an indication for kidney replacement therapy, including either dialysis or transplantation. Among patients who are on dialysis, symptoms are an indication to increase the amount of dialysis, even if the minimum target Kt/V is being achieved with the current prescription. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic treatment</strong> – For patients with persistent symptoms despite dialysis, pharmacologic treatment of neuropathy may be effective. Pharmacologic therapies that have been used are the same as for other types of polyneuropathy and include <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> and tricyclic antidepressants. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– Symptoms may persist even after many years of dialysis but are usually completely reversed with kidney transplantation. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H2676674028"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges William L Henrich, MD, MACP, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Raskin NH, Fishman RA. Neurologic disorders in renal failure (first of two parts). N Engl J Med 1976; 294:143.</a></li><li><a class="nounderline abstract_t">Fraser CL, Arieff AI. Nervous system complications in uremia. Ann Intern Med 1988; 109:143.</a></li><li><a class="nounderline abstract_t">Krishnan AV, Kiernan MC. Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve 2007; 35:273.</a></li><li><a class="nounderline abstract_t">Guolo M, Stella AM, Melito V, et al. Altered 5-aminolevulinic acid metabolism leading to pseudoporphyria in hemodialysed patients. Int J Biochem Cell Biol 1996; 28:311.</a></li><li><a class="nounderline abstract_t">Tegnér R, Lindholm B. Uremic polyneuropathy: different effects of hemodialysis and continuous ambulatory peritoneal dialysis. Acta Med Scand 1985; 218:409.</a></li><li><a class="nounderline abstract_t">Lindsay RM, Bolton CF, Clark WF, Linton AL. The effect of alterations of uremic retention products upon platelet and peripheral nerve function. Clin Nephrol 1983; 19:110.</a></li><li><a class="nounderline abstract_t">Bansal VK, Bansal S. Nervous system disorders in dialysis patients. Handb Clin Neurol 2014; 119:395.</a></li><li><a class="nounderline abstract_t">Arnold R, Pianta TJ, Pussell BA, et al. Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD. Clin J Am Soc Nephrol 2017; 12:1569.</a></li><li class="breakAll">Bolton CF, Young GB. Uremic neuropathy. In: Neurological Complications of Renal Disease, Butterworth (Ed), Boston 1990. p.76.</li><li><a class="nounderline abstract_t">Baumgaertel MW, Kraemer M, Berlit P. Neurologic complications of acute and chronic renal disease. Handb Clin Neurol 2014; 119:383.</a></li><li><a class="nounderline abstract_t">Laaksonen S, Metsärinne K, Voipio-Pulkki LM, Falck B. Neurophysiologic parameters and symptoms in chronic renal failure. Muscle Nerve 2002; 25:884.</a></li><li><a class="nounderline abstract_t">Krishnan AV, Phoon RK, Pussell BA, et al. Altered motor nerve excitability in end-stage kidney disease. Brain 2005; 128:2164.</a></li><li><a class="nounderline abstract_t">Aggarwal HK, Sood S, Jain D, et al. Evaluation of spectrum of peripheral neuropathy in predialysis patients with chronic kidney disease. Ren Fail 2013; 35:1323.</a></li><li><a class="nounderline abstract_t">Yosipovitch G, Yarnitsky D, Mermelstein V, et al. Paradoxical heat sensation in uremic polyneuropathy. Muscle Nerve 1995; 18:768.</a></li><li><a class="nounderline abstract_t">Makkar RK, Kochar DK. Somatosensory evoked potentials (SSEPs); sensory nerve conduction velocity (SNCV) and motor nerve conduction velocity (MNCV) in chronic renal failure. Electromyogr Clin Neurophysiol 1994; 34:295.</a></li><li><a class="nounderline abstract_t">Brouns R, De Deyn PP. Neurological complications in renal failure: a review. Clin Neurol Neurosurg 2004; 107:1.</a></li><li><a class="nounderline abstract_t">Ropper AH. Accelerated neuropathy of renal failure. Arch Neurol 1993; 50:536.</a></li><li><a class="nounderline abstract_t">Rodríguez-Iturbe B, García R, Rubio L, et al. Acute glomerulonephritis in the Guillain-Barré-Strohl syndrome. Report of nine cases. Ann Intern Med 1973; 78:391.</a></li><li><a class="nounderline abstract_t">Panjwani M, Truong LD, Eknoyan G. Membranous glomerulonephritis associated with inflammatory demyelinating peripheral neuropathies. Am J Kidney Dis 1996; 27:279.</a></li><li><a class="nounderline abstract_t">Ho DT, Rodig NM, Kim HB, et al. Rapid reversal of uremic neuropathy following renal transplantation in an adolescent. Pediatr Transplant 2012; 16:E296.</a></li><li><a class="nounderline abstract_t">Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280:1831.</a></li><li><a class="nounderline abstract_t">Bazzi C, Pagani C, Sorgato G, et al. Uremic polyneuropathy: a clinical and electrophysiological study in 135 short- and long-term hemodialyzed patients. Clin Nephrol 1991; 35:176.</a></li><li><a class="nounderline abstract_t">Said G. Uremic neuropathy. Handb Clin Neurol 2013; 115:607.</a></li></ol></div><div id="topicVersionRevision">Topic 1837 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1105188" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Neurologic disorders in renal failure (first of two parts).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2837930" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Nervous system complications in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17195171" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Uremic neuropathy: clinical features and new pathophysiological insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8920640" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Altered 5-aminolevulinic acid metabolism leading to pseudoporphyria in hemodialysed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4083083" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Uremic polyneuropathy: different effects of hemodialysis and continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6839559" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The effect of alterations of uremic retention products upon platelet and peripheral nerve function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24365308" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Nervous system disorders in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28893921" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28893921" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24365307" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Neurologic complications of acute and chronic renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12115978" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Neurophysiologic parameters and symptoms in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15947058" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Altered motor nerve excitability in end-stage kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23964701" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Evaluation of spectrum of peripheral neuropathy in predialysis patients with chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7783767" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Paradoxical heat sensation in uremic polyneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7956880" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Somatosensory evoked potentials (SSEPs); sensory nerve conduction velocity (SNCV) and motor nerve conduction velocity (MNCV) in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15567546" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Neurological complications in renal failure: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8387770" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Accelerated neuropathy of renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4694895" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Acute glomerulonephritis in the Guillain-Barré-Strohl syndrome. Report of nine cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8659507" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Membranous glomerulonephritis associated with inflammatory demyelinating peripheral neuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22188489" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Rapid reversal of uremic neuropathy following renal transplantation in an adolescent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9846777" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1649712" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Uremic polyneuropathy: a clinical and electrophysiological study in 135 short- and long-term hemodialyzed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23931805" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Uremic neuropathy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
